CN104024246B - 作为欧若拉激酶抑制剂的取代嘧啶衍生物 - Google Patents

作为欧若拉激酶抑制剂的取代嘧啶衍生物 Download PDF

Info

Publication number
CN104024246B
CN104024246B CN201380004705.4A CN201380004705A CN104024246B CN 104024246 B CN104024246 B CN 104024246B CN 201380004705 A CN201380004705 A CN 201380004705A CN 104024246 B CN104024246 B CN 104024246B
Authority
CN
China
Prior art keywords
alkyl
cancer
alkoxy
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380004705.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104024246A (zh
Inventor
张英俊
刘兵
张健存
张吉泉
杨学绮
李燕平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Guangdong HEC Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical Co Ltd filed Critical Guangdong HEC Pharmaceutical Co Ltd
Priority to CN201380004705.4A priority Critical patent/CN104024246B/zh
Publication of CN104024246A publication Critical patent/CN104024246A/zh
Application granted granted Critical
Publication of CN104024246B publication Critical patent/CN104024246B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380004705.4A 2012-03-27 2013-03-27 作为欧若拉激酶抑制剂的取代嘧啶衍生物 Active CN104024246B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380004705.4A CN104024246B (zh) 2012-03-27 2013-03-27 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210083444.7 2012-03-27
CN201210083444 2012-03-27
CN2012100834447 2012-03-27
PCT/CN2013/073290 WO2013143466A1 (fr) 2012-03-27 2013-03-27 Dérivé de pyrimidine substitué en tant qu'inhibiteur des kinases aurora
CN201380004705.4A CN104024246B (zh) 2012-03-27 2013-03-27 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN104024246A CN104024246A (zh) 2014-09-03
CN104024246B true CN104024246B (zh) 2016-03-02

Family

ID=49258228

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380004705.4A Active CN104024246B (zh) 2012-03-27 2013-03-27 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Country Status (2)

Country Link
CN (1) CN104024246B (fr)
WO (1) WO2013143466A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
KR101726648B1 (ko) * 2016-02-29 2017-04-14 한국화학연구원 신규한 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 drak 관련 질환의 예방 또는 치료용 약학적 조성물
TWI667236B (zh) * 2017-06-13 2019-08-01 財團法人國家衛生研究院 作為蛋白激酶抑制劑的胺基噻唑化合物
CN115925684B (zh) * 2021-12-03 2025-02-28 徐诺药业(南京)有限公司 一种嘧啶类衍生物及其制备方法和应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
EP4725942A1 (fr) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Composés actifs sur la voie de la cycline d1 et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675199A (zh) * 2002-06-20 2005-09-28 沃泰克斯药物股份有限公司 制备作为蛋白激酶抑制剂的取代的嘧啶和嘧啶衍生物的方法
CN101316587A (zh) * 2005-09-30 2008-12-03 迈卡纳治疗股份有限公司 取代的吡唑化合物
CN101675041A (zh) * 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物
CN101870690A (zh) * 2004-06-04 2010-10-27 艾尼纳制药公司 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055491A1 (fr) * 2001-12-24 2003-07-10 Astrazeneca Ab Derives de la quinazoline substitues utilises en tant qu'inhibiteurs des kinases aurora
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675199A (zh) * 2002-06-20 2005-09-28 沃泰克斯药物股份有限公司 制备作为蛋白激酶抑制剂的取代的嘧啶和嘧啶衍生物的方法
CN101870690A (zh) * 2004-06-04 2010-10-27 艾尼纳制药公司 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
CN101316587A (zh) * 2005-09-30 2008-12-03 迈卡纳治疗股份有限公司 取代的吡唑化合物
CN101675041A (zh) * 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物

Also Published As

Publication number Publication date
CN104024246A (zh) 2014-09-03
WO2013143466A1 (fr) 2013-10-03

Similar Documents

Publication Publication Date Title
CN104024246B (zh) 作为欧若拉激酶抑制剂的取代嘧啶衍生物
KR102216284B1 (ko) Dna-pk 억제제
JP5406725B2 (ja) タンパク質キナーゼ阻害剤として有用な化合物
CN110036005B (zh) 酰胺衍生物及其在药物中的应用
US7998987B2 (en) Inhibitors of c-Met and uses thereof
CN105636958B (zh) Dna‑pk抑制剂
CN104640852B (zh) Dna‑pk抑制剂
CN101883764B (zh) 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
JP5869338B2 (ja) タンパク質キナーゼ阻害剤
CN115279749A (zh) Shp2抑制剂及其组合物和应用
CN113166156B (zh) 酪氨酸激酶抑制剂、组成及其方法
CN104098551A (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN109251166B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
CN109988106B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
RS55793B1 (sr) 6-alkinil piridini kao smac mimetici
CN102481285A (zh) 吲哚的衍生物用于治疗癌症的用途
CN108218873A (zh) 流感病毒复制抑制剂及其用途
CN116568308A (zh) 一类杂环类shp2抑制剂、其制备方法及用途
CN111196806B (zh) 胍类衍生物及其用途
CN105461709B (zh) 取代脲衍生物及其在药物中的应用
WO2024167927A1 (fr) Composés, compositions et leurs procédés d'utilisation
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
KR20250164110A (ko) Lrrk2억제제로서의 헤테로사이클 화합물
CA3220090A1 (fr) Composes de pyrimidine et d'amine de pyridine et leur utilisation dans le traitement de maladies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address